A strategy for testing established human plasma protein manufacturing procedures for their ability to inactivate or eliminate human immunodeficiency virus
- 1 January 1987
- journal article
- research article
- Published by Elsevier in Journal of Biological Standardization
- Vol. 15 (3) , 251-263
- https://doi.org/10.1016/0092-1157(87)90028-x
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- ISOLATION OF RETROVIRUSES FROM TWO PATIENTS WITH "COMMON VARIABLE" HYPOGAMMAGLOBULINAEMIAThe Lancet, 1986
- The natural history of human T lymphotropic virus-III infection: the cause of AIDS.BMJ, 1986
- Transmission of Lymphotropic Retroviruses (HTLV-I and LAV/HTLV-III) by Blood Transfusion and Blood ProductsVox Sanguinis, 1986
- The Epidemiology of AIDS: Current Status and Future ProspectsScience, 1985
- DETECTION OF INFECTIOUS HTLV-III/LAV VIRUS IN CELL-FREE PLASMA FROM AIDS PATIENTSThe Lancet, 1985
- Human T-Lymphotropic Retrovirus Type III / Lymphadenopathy-Associated Virus AntibodyPublished by American Medical Association (AMA) ,1985
- Serologic tests for HTLV-III antibodies: Methods and interpretationsClinical Microbiology Newsletter, 1985
- INABILITY OF PASTEURISED FACTOR VIII PREPARATIONS TO INDUCE ANTIBODIES TO HTLV-III AFTER LONG-TERM TREATMENTThe Lancet, 1985
- HTLV-III IN SYMPTOM-FREE SERONEGATIVE PERSONSThe Lancet, 1984
- HIGH PREVALENCE OF LYMPHADENOPATHY VIRUS (LAV) IN EUROPEAN HAEMOPHILIACSThe Lancet, 1984